Fisetin and Quercetin

Supplement–drug interaction evidence from the TruthStack database.

SeverityMODERATE
Evidence TierModerate
Interaction TypeSAFETY CONCERN
MechanismPHARMACODYNAMIC
Last Reviewed2026-02-15

Summary

Both are senolytics that inhibit BCL-2 family proteins. Published protocols (dasatinib+quercetin trials) use intermittent pulsed dosing, not continuous daily use. Long-term daily senolytic exposure at relevant doses is not well-studied in humans. If senolytic benefit is the goal, review pulsed-dosing protocols with clinician.

API Reference

GET https://api.truthstack.co/v1/check?c1=Fisetin&c2=Quercetin

Open, unauthenticated. Returns JSON. Developer documentation

Related Interactions

What this page is and is not. TruthStack is an informational reference database that describes published pharmacological findings. It does not provide medical advice, diagnosis, or treatment recommendations. The information on this page reflects flags in our database and should not replace consultation with a qualified healthcare provider. Always discuss supplement-drug combinations with your prescriber or pharmacist.